• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    The Broken Brown Egg and Progyny Announce the 2025 Awareness, Hope, and Activism Grant™ to Support BIPOC Individuals and Couples in Family Building

    4/8/25 8:57:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email

    NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, and The Broken Brown Egg, a nonprofit supporting BIPOC individuals and couples experiencing infertility, today announced the launch of their 2025 Awareness, Hope, and Activism (AHA) Grant, marking the fourth consecutive year of this family building partnership.

    The AHA Grant is an extension of the Broken Brown Egg's mission to break down the unique barriers that Black individuals face when pursuing fertility and family building care. These challenges include financial obstacles, health disparities, and persistent social stigmas that often go unaddressed in traditional healthcare settings. By providing comprehensive support through education, specialized treatment access, financial assistance, and emotional resources, the grant creates pathways to parenthood that might otherwise remain out of reach.

    "Every year I'm moved by the stories of resilience from our community members navigating fertility challenges," said Regina Townsend, Founder, The Broken Brown Egg. "This fourth year of the AHA Grant represents our growing impact and unwavering commitment to ensuring BIPOC individuals don't face these journeys alone. That true 'AHA moment' isn't just about awareness—it's about empowerment through opening the door to new possibilities on the path to parenthood."

    In addition to financial support for treatment, recipients of this year's grant will also receive enhanced medication support through Alto Pharmacy, a digitally powered pharmacy specializing in fertility care. Alto's comprehensive approach includes access to expert pharmacists seven days a week and flexible delivery options—including same-day courier service—ensuring medications arrive when and where patients need them most. Additionally, grant recipients will benefit from unlimited access to a dedicated Progyny Patient Care Advocate who will serve as their personal fertility coach, offering clinical education, guidance, and emotional support throughout their entire family building journey.

    "At Progyny, we believe family building should be accessible to everyone," said Janet Choi, MD, MSCP, Chief Medical Officer, Progyny. "Through our continued partnership with The Broken Brown Egg, we're addressing the systemic inequities that have historically limited options for BIPOC individuals. When we combine evidence-based clinical resources with culturally competent support systems, we achieve outcomes that extend beyond individual treatments —we nurture hope and create lasting change for everyone."

    The grant application opens today, April 8, 2025, and welcomes submissions from U.S. citizens and legal residents aged 18-45. Applications will be accepted through May 12, with winners—selected by a distinguished panel of BIPOC infertility advocates and physicians—announced on May 19. For complete application instructions and eligibility requirements, visit The Broken Brown Egg's grant website at https://thebrokenbrownegg.org/aha-grant.

    For more information on Progyny, visit www.progyny.com.

    About Progyny

    Progyny (NASDAQ:PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians.

    Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.

    Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.

    About The Broken Brown Egg

    The Broken Brown Egg, Inc. exists to inform, empower, and advocate for individuals and couples experiencing infertility and reproductive health issues, with an emphasis on the Black experience of these concerns.

    The Broken Brown Egg dismantles the stigmas associated with fertility in underserved populations through relatable and accessible programs and events. The organization provides resources and support for three major targets: Reproductive Justice and Health Equity, The Reproductive Health Careers Pipeline, and Empowerment & Community Building. Signature programming includes an online virtual support community, an annual Mother's Day wine sip for those experiencing infertility, and a robust empowerment network connecting researchers and journalists to participants of color.

    The Broken Brown Egg, Inc. is a 501c3 tax-exempt organization headquartered in Chicago, Illinois. For more information, please visit www.thebrokenbrownegg.org.

    For Further Information, Please Contact:

    Media:

    Alexis Ford

    [email protected]



    Primary Logo

    Get the next $PGNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    1/20/2026$30.00Mkt Perform → Mkt Outperform
    Citizens JMP
    1/8/2026$34.00Hold → Buy
    Truist
    12/9/2025$29.00Overweight
    Barclays
    11/12/2025$30.00Sector Weight → Overweight
    KeyBanc Capital Markets
    7/8/2025$28.00Market Perform → Outperform
    Leerink Partners
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    9/19/2024Mkt Outperform → Mkt Perform
    JMP Securities
    More analyst ratings

    $PGNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Progyny upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Progyny from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    1/20/26 8:45:21 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny upgraded by Truist with a new price target

    Truist upgraded Progyny from Hold to Buy and set a new price target of $34.00

    1/8/26 9:26:52 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Barclays initiated coverage on Progyny with a new price target

    Barclays initiated coverage of Progyny with a rating of Overweight and set a new price target of $29.00

    12/9/25 8:52:58 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Progyny Commemorates 10 Years of Redefining Women's Health and Family Building Care

    NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Over the past ten years, millions of individuals and families have gained access to life-changing benefits through Progyny, a global leader in women's health and family building solutions. Progyny today announces that throughout the year, it will honor the collective efforts of its members, employers, providers, and industry partners who have helped shape this decade of progress. The company has redefined what's possible in the benefits industry by combining clinical expertise, innovation, and a personalized approach to support members at every stage, from preconception through menopause. "Ten years ago, we set out to transform family building

    4/1/26 9:23:11 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Executives to Participate in Upcoming Investor Conferences

    NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that several members of its leadership team will participate in upcoming investor conferences in March, including the Leerink Partners Global Healthcare Conference, the Barclays Global Healthcare Conference, and the KeyBanc Capital Markets Healthcare Forum. At the Leerink Partners Global Healthcare Conference, Mark Livingston, Chief Financial Officer, will participate in a fireside chat on March 10, 2026, at 10:40 a.m. Eastern Time. At the Barclays Global Healthcare Conference, Pete Anevski, Chief Executive Officer, will participate in

    3/6/26 9:02:47 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Fourth Quarter 2025 Results

    Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent AuthorizationIssues Financial Guidance for 2026, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three- and twelve-month periods ended December 31, 2025 ("the fourth quarter of 2025" and "the full year", resp

    2/26/26 4:01:00 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Clapp Geoffrey

    4 - Progyny, Inc. (0001551306) (Issuer)

    3/19/26 5:12:56 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    EVP, GC Swartz Allison covered exercise/tax liability with 339 shares and sold $10,506 worth of shares (599 units at $17.54), decreasing direct ownership by 1% to 88,941 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    3/6/26 4:36:37 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 339 shares, decreasing direct ownership by 0.39% to 87,338 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    3/6/26 4:35:02 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Anevski Peter bought $1,930,896 worth of shares (79,500 units at $24.29), increasing direct ownership by 13% to 680,251 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    11/17/25 8:22:02 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Executive Chairman Schlanger David J bought $2,202,330 worth of shares (150,000 units at $14.68), increasing direct ownership by 192% to 228,269 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    12/26/24 5:35:03 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    CHIEF EXECUTIVE OFFICER Anevski Peter bought $3,034,084 worth of shares (209,500 units at $14.48), increasing direct ownership by 90% to 441,463 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    12/26/24 5:31:32 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    SEC Filings

    View All

    SEC Form PRE 14A filed by Progyny Inc.

    PRE 14A - Progyny, Inc. (0001551306) (Filer)

    3/31/26 4:33:46 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.

    SCHEDULE 13G/A - Progyny, Inc. (0001551306) (Subject)

    3/27/26 11:19:23 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Progyny, Inc. (0001551306) (Filer)

    3/13/26 4:15:27 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Leadership Updates

    Live Leadership Updates

    View All

    Progyny CEO Named World Economic Forum Champion for Women's Health

    NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that CEO Pete Anevski has been honored with the recognition as a Champion for Women's Health by the World Economic Forum (the Forum) and the Global Alliance for Women's Health (GAWH). The community of Champions is a distinguished group of global leaders who are playing a critical role in driving advocacy efforts, shaping policies, fostering innovation, and unlocking investments to advance women's health. The exclusive Champions community spans diverse sectors, industries, and geographies, and includes figures such as: Helen Clark, former

    10/7/25 9:30:50 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Appoints Two Renowned Women's Health Experts to Medical Advisory Board

    NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the appointment of Morehouse School of Medicine's Regional Dean for Seattle and Puget Sound's Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (MSCP) – and Columbia University's Dr. Whitney Booker – a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine – to its Medical Advisory Board. "As Pr

    5/14/25 9:05:48 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

    NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

    4/17/25 9:36:59 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Financials

    Live finance-specific insights

    View All

    Progyny, Inc. Announces Fourth Quarter 2025 Results

    Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent AuthorizationIssues Financial Guidance for 2026, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three- and twelve-month periods ended December 31, 2025 ("the fourth quarter of 2025" and "the full year", resp

    2/26/26 4:01:00 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report

    NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period and full year ended December 31, 2025, after the close of the market on Thursday, February 26, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using t

    2/12/26 2:46:53 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Third Quarter 2025 Results

    Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and Near 100% Retention of Existing BaseRecord $156.0 Million in Operating Cash Flow Generated over the First Nine Months of 2025Board Authorizes Up to $200 Million in Share Repurchase Program NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended September 30, 2025 ("the third quarter of 2025"), as compared to the th

    11/6/25 4:01:00 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    12/6/24 10:11:35 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    11/14/24 4:31:23 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Progyny Inc. (Amendment)

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    2/14/24 6:29:49 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care